Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies

Journal:
Blood
Published:
Affiliations:
19
Authors:
33
Institutions Authors Share
Wugen, Inc., United States of America (USA)
13.000000
13.000000
0.39
Washington University in St. Louis (WUSTL), United States of America (USA)
4.000000
0.12
USC Children's Hospital Los Angeles (CHLA), United States of America (USA)
1.500000
0.05
USC Norris Comprehensive Cancer Center, United States of America (USA)
1.500000
0.05
Princess Maxima Centre for Pediatric Oncology (PMC), Netherlands
1.500000
0.05
City of Hope, United States of America (USA)
1.000000
0.03
Children's Hospital of Philadelphia (CHOP), United States of America (USA)
1.000000
0.03
Vanderbilt University Medical Center (VUMC), United States of America (USA)
1.000000
0.03
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)
1.000000
0.03
University of Wisconsin Carbone Cancer Center (UWCCC), United States of America (USA)
1.000000
0.03
Erasmus University Medical Center (Erasmus MC), Netherlands
1.000000
0.03
Robert Debré University Hospital, France
1.000000
0.03
Mersana Therapeutics, United States of America (USA)
1.000000
0.03
Alviso Clinical Research, United States of America (USA)
1.000000
0.03
Peter MacCallum Cancer Centre (Peter Mac), Australia
0.500000
0.02
Royal Melbourne Hospital (RMH), Australia
0.500000
0.02
Erasmus MC-Sophia, Netherlands
0.500000
0.02
Hôpital Saint-Louis, France
0.500000
0.02
Paris Cité University, France
0.500000
0.02